SCHEMBL8220004

SCHEMBL8220004

O=C(O)c1cc(C(=O)O)c(Br)cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.60
ASPH Q12797 10/20 0.60
KDM8 Q8N371 9/20 0.60
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
RIOX2 Q8IUF8 7/20 0.45
DDT P30046 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
P4HA1 P13674 1/20 0.41
MIF P14174 1/20 0.41
P4HTM Q9NXG6 1/20 0.41
EGLN1 Q9GZT9 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26140194 0.82 KDM4E (0.46) KDM4EASPHKDM8ALDH1A1RIOX2
SCHEMBL2249284 0.81 HSD17B10 (0.43) KDM4EASPHKDM8ALDH1A1SMN1; SMN2
SCHEMBL1171098 0.80 KDM4E (0.67) KDM4EASPHKDM8ALDH1A1SMN1; SMN2
SCHEMBL27106805 0.79 KDM4E (0.48) KDM4EASPHKDM8ALDH1A1SMN1; SMN2
SCHEMBL21826652 0.79 AKR1C4 (0.44) KDM4EASPHKDM8ALDH1A1SMN1; SMN2
SCHEMBL3879991 0.78 ALDH1A1 (0.49) KDM4EASPHKDM8ALDH1A1SMN1; SMN2
SCHEMBL2262851 0.78 KDM4E (0.47) KDM4EASPHKDM8ALDH1A1SMN1; SMN2
SCHEMBL31090134 0.78 KDM4E (0.47) KDM4EASPHKDM8ALDH1A1SMN1; SMN2
SCHEMBL1180456 0.78 KDM4E (0.52) KDM4EASPHKDM8ALDH1A1SMN1; SMN2
SCHEMBL4790109 0.78 GABRP (0.56) KDM4EASPHKDM8ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492187-B2 Factor XI activation inhibitors MERCK SHARP & DOHME LLC (US) 2025-12-09 US disclosed
US-20230147170-A1 FACTOR XI ACTIVATION INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-05-11 US disclosed
US-20230147170-A1 FACTOR XI ACTIVATION INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-05-11 US disclosed
US-20230147170-A1 FACTOR XI ACTIVATION INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-05-11 US disclosed
EP-4125892-A1 FACTOR XI ACTIVATION INHIBITORS Merck Sharp & Dohme LLC (US) 2023-02-08 EP disclosed
WO-2021202254-A1 FACTOR XI ACTIVATION INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-10-07 WO disclosed
WO-2021202254-A1 FACTOR XI ACTIVATION INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-10-07 WO disclosed
EP-2816038-B1 HOPO CHELATORS LUMIPHORE INC (US) 2019-11-20 EP disclosed
US-10352938-B2 Macrocyclic HOPO chelators LUMIPHORE, INC. (US) 2019-07-16 US disclosed
US-20160320399-A1 MACROCYCLIC HOPO CHELATORS LUMIPHORE, INC. 2016-11-03 US disclosed
EP-2470513-B1 MACROCYCLIC HOPO CHELATORS LUMIPHORE INC (US) 2014-10-08 EP disclosed
US-20120214253-A1 MACROCYCLIC HOPO CHELATORS LUMIPHORE, INC. (US) 2012-08-23 US disclosed
EP-2470513-A1 MACROCYCLIC HOPO CHELATORS Lumiphore, Inc. (US) 2012-07-04 EP disclosed
WO-2011025790-A1 MACROCYCLIC HOPO CHELATORS LUMIPHORE, INC. (US) 2011-03-03 WO disclosed
US-5356909-A Substituted pyridine-2,4-dicarboxylic acid compounds and the use thereof and medicaments HOECHST AKTIENGESELLSCHAFT (DE) 1994-10-18 US disclosed
EP-0281943-B1 Substituted pyridine-2,4-carboxylic acid derivatives, process for their preparation, their use as well as medicaments based on these compounds HOECHST AG (DE) 1994-01-12 EP disclosed
EP-0548883-A1 Substituted pyridine-N-oxides, process for their preparation and their use as medicines HOECHST AKTIENGESELLSCHAFT (DE) 1993-06-30 EP disclosed
US-5143926-A Substituted pyridine-2,4-dicarboxylic acid compounds and methods of use thereof HOECHST AKTIENGESELLSCHAFT (DE) 1992-09-01 US disclosed
US-5004748-A Substituted pyridine-2,4-dicarboxylic acid derivatives and medicaments based on these compounds HOECHST AKTIENGESELLSCHAFT (DE) 1991-04-02 US disclosed
EP-0281943-A2 Substituted pyridine-2,4-carboxylic acid derivatives, process for their preparation, their use as well as medicaments based on these compounds HOECHST AKTIENGESELLSCHAFT (DE) 1988-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12492187-B2 Factor XI activation inhibitors F11, TFPI, F13B KDM4E 1614/4885ASPH 890/4885KDM8 476/4885
US-20230147170-A1 FACTOR XI ACTIVATION INHIBITORS F11, TFPI, F13B KDM4E 1614/4885ASPH 890/4885KDM8 476/4885
US-20160320399-A1 MACROCYCLIC HOPO CHELATORS PHPT1, SSB, CD69 KDM4E 2605/4885ASPH 1698/4885KDM8 1771/4885
US-20120214253-A1 MACROCYCLIC HOPO CHELATORS PHPT1, SSB, CD69 KDM4E 2605/4885ASPH 1698/4885KDM8 1771/4885
US-10352938-B2 Macrocyclic HOPO chelators PHPT1, SSB, CD69 KDM4E 2605/4885ASPH 1698/4885KDM8 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.